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In May 2012 at the World Health
Assembly, member states of the World
Health Organization (WHO) have the
opportunity to make substantial progress
on a major global health challenge: how to
catalyse new knowledge for diseases that
primarily affect the global poor and for
which patents provide insufficient market
incentives. The existing system can neither
adequately develop nor deliver health
technologies addressing health concerns
mainly or only constituting a problem in
developing countries. Those markets have
no ability to pay the high prices needed to
recover research and development (R&D)
costs, which is the way the current system
operates. We need mechanisms that delink
the cost of R&D from the price of products.
There have been many positive efforts
to tackle these issues, including the estab-
lishment of diverse public–private product
development partnerships (PDPs) like the
Medicines for Malaria Venture and Drugs
for Neglected Diseases initiative. But these
efforts have only treated the symptoms
exhibited by the system failures and not
the root causes. WHO has been the arena
for discussion and analysis of these issues
for 10 years including the work of the
Commission on Intellectual Property
Rights, Innovation and Public Health
and the agreement on a Global Strategy
and Plan of Action on Public Health,
Innovation and Intellectual Property [1,2].
But sustainable solutions for access to
medicines have not been established.
More than a hundred proposals have been
put forward by submissions from different
stakeholders during these processes and to
follow on expert groups, but the approach-
es are often fragmented and sometimes
competing. Last month the Consultative
Expert Working Group on Research and
Development (CEWG), which we have
had the honour of chairing, published a
comprehensive analysis concluding with a
set of bold recommendations for the WHA
to consider [3].
Acting upon the CEWG recommenda-
tions would constitute a transformative
change rather than an incremental im-
provement. We do call for more money—
this is not new in global health, but even
more importantly we call for money that is
used in smarter ways. We propose new
strategies for how research in this area can
be conducted and a new paradigm for how
financial contributions should be deter-
mined based on the concept that both the
costs and benefits of R&D should be
shared. We recommend a role for WHO
in the stronger coordination of R&D and
suggest pooling of financial investments to
secure efficient allocations to where de-
mands and opportunities are identified
through active participation of developing
countries.
We recommend the creation of a system
complementary to the existing intellectual
property regime in which patents currently
constitute the main incentive for invest-
ment. We call for R&D conducted within
an open knowledge innovation framework
where knowledge is either in the public
domain or free to use through appropriate
licensing arrangements. Such ‘‘open’’ ap-
proaches have been used successfully in
other sectors and foster innovation. This
will allow for products to be delivered at
competitive prices that developing coun-
tries can afford. We also recommend more
extensive use of patent pools to better
share knowledge, and to use prizes as an
incentive mechanism for discovering new
products.
Today, developing countries must rely
on their own limited financial and human
resources to develop technologies they
need, or they must depend on aid or
technology transfers based on charity or
political decisions. Neither the self-suffi-
ciency nor the charitable approaches are
sustainable. Our proposal constitutes a
third way forward where these R&D
investments are treated like the global
public goods they are such that all
countries—rich and poor, developed and
developing alike—contribute according to
the size of their economy. This conceptu-
alization of R&D investments also under-
scores that it is inefficient to generate
knowledge that cannot be fully exploited
and that all countries should pay their
share of this global resource. Based on
analysis of current needs and investments,
we are recommending countries allocate
at least 0.01% of GDP to this global public
good, which would result in a doubling of
current investments.
The major challenge for new policies is
not to get agreement on them, but to make
them acted upon and fully implemented.
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versus hard law approaches to making
globally agreed upon policies deliver.
Some argue that the only way to get
agreement on strong and specific enough
measures is through soft laws, since hard
laws often end with watered down com-
mitments, and that soft law thereby can
achieve more. However, the reason for
soft laws to be more easily agreed upon is
exactly that they are less committing. This
line of argument then ends with two
options: soft laws with clear commitments
but which are not committed to, or hard
laws with weak commitments that are
committed to. Both options can end with
poor policy outcomes. Our firm belief is
that it is time to break this Catch-22. The
CEWG proposes that our set of recom-
mendations should be combined in a
legally binding instrument with clear
commitments; a new international con-
vention.
So far, the only existing international
health laws adopted under the WHO
Constitution are the Framework Conven-
tion on Tobacco Control and the Inter-
national Health Regulations. These can be
said to be regulating ‘‘global public bads’’
in that they either reduce sales and
consumption of a harmful product or
reduce the transmission of infectious
agents. It is time to also regulate the
commitments needed to produce ‘‘global
public goods’’. We should learn from the
environmental sector where the Multilat-
eral Fund to protect the ozone layer and
the new Green Climate Fund have been
established through conventions. We be-
lieve that a convention on global health
R&D meets the necessary criteria for when
international health law is an appropriate
instrument [4]. It is a way to secure a
systemic and sustainable solution since it
creates a formalized platform for the
future where countries can be held
accountable.
We know that our recommendations
will be met by both applause and scepti-
cism. Systemic changes will always be
difficult since many interests are at stake.
This is why the status quo is so resilient.
However, the millions of potentially pre-
ventable deaths each year demand chang-
es. We must be willing to endure a phase
of disequilibrium [5]. This requires lead-
ership and we hope WHO can provide
such adaptive leadership. We believe our
report will be a good platform for member
states of WHO to enter into negotiations
to establish a convention for global health
R&D. They must not be caught up in time
wasting and exhausting processes. Now is
the time.
Author Contributions
Wrote the first draft of the manuscript: JAR.
Contributed to the writing of the manuscript:
JAR CC. ICMJE criteria for authorship read
and met: JAR CC. Agree with manuscript
results and conclusions: JAR CC.
References
1. Commission on Intellectual Property Rights,
Innovation and Public Health (2006) Public health,
innovation and intellectual property rights. Gene-
va: Commission on Intellectual Property Rights,
Innovation and Public Health. Available: http://
www.who.int/intellectualproperty/report/en/
index.html. Accessed 12 April 2012.
2. World Health Assembly (2008) Global strategy and
plan of action on public health, innovation and
intellectual property (WHA61.21). Available:
http://apps.who.int/gb/ebwha/pdf_files/
WHA61-REC1/A61_Rec1-part2-en.pdf. Accessed
12 April 2012.
3. WHO (2012) Research and development to meet
health needs in developing countries: strengthening
global financing and coordination. Report of the
Consultative Expert Working Group on Research
and Development: Financing and Coordination.
Geneva: WHO, Available: http://www.who.int/
phi/CEWG_Report_5_April_2012.pdf. Accessed
12 April 2012.
4. Hoffman SJ, Røttingen JA (2011) A framework
convention on obesity control? Lancet 378: 2068.
5. Heifetz R (1994) Leadership without easy answers.
Cambridge: Belknap/Harvard University Press.
PLoS Medicine | www.plosmedicine.org 2 May 2012 | Volume 9 | Issue 5 | e1001219